ATLANTIS Trial Results for Patients Treated Within 3 Hours of Stroke Onset
نویسنده
چکیده
Background and Purpose—Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods—We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results—Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of 1) on the National Institutes of Health Stroke Scale at 90 days (P 0.01). Conclusions—These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset. (Stroke. 2002;33:493-496.)
منابع مشابه
ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
BACKGROUND AND PURPOSE Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. METHODS We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours ...
متن کاملAre some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?
BACKGROUND AND PURPOSE Recombinant tissue plasminogen activator (rtPA) has been demonstrated to improve outcomes in acute ischemic stroke when delivered within 3 hours of symptom onset. However, the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS B) trial, in which patients were treated mostly between 3 and 5 hours after symptom onset, found no overall be...
متن کاملThe 4.5-hour time window for intravenous thrombolysis with intravenous tissue-type plasminogen activator is not firmly established.
M ost stroke neurologists would likely choose to treat this patient with intravenous tissue-type plasminogen activator (IV tPA) assuming the treatment could be initiated within 4.5 hours from stroke onset. In fact, the American Heart Association and European Stroke Organization guidelines both recommend treatment of selected patients in the 3-to 4.5-hour time window. IV tPA is approved in this ...
متن کاملRecombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke
THE FOOD AND DRUG ADMINIStration (FDA) approval in June 1996 of intravenous recombinant tissue-type plasminogen activator (rt-PA) for patients with acute ischemic stroke treated within 3 hours of symptom onset marked a historic first step in treating this devastating disease. This approval was primarily based on the results of the National Institute of Neurologic Disorders (NINDS) trials (1 and...
متن کاملTreatment of acute ischemic stroke: Part I: recanalization strategies.
59. Adams H Jr, Brott T, Furlan A, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke (AHA Medical/Scientific Statement). Circulation. 1996;94:1167–1174. 60. Patel SC, Levine SR, Tilley BC, et al, for the National Institute of Neurological Disorders, and Stroke rt-PA Stroke Study Group. Lack of cl...
متن کامل